Tight Control of Gouty Arthritis Compared to Flare Based Treatment Escalation (TICOGA)
Gout
About this trial
This is an interventional health services research trial for Gout
Eligibility Criteria
Inclusion Criteria:
- Provision of informed consent.
- Age ≥18 years.
- Patient has sustained at least one flare of gout in the previous 12 months.
- Confirmed clinical diagnosis of gout as per ACR/EULAR criteria
- Serum urate >0.36mm/L.
- Patient has a smart phone and is able to install GoutSMART application.
Exclusion Criteria:
- Subject unable to provide consent
- Patient on maximum urate lowering therapy or where therapy cannot be escalated further due to intolerance/adverse reaction to either allopurinol or febuxostat.
- End stage renal failure/transplant or established liver disease
- Current prescription of medication known to interact with xanthine oxidase inhibitors such as azathioprine or mercapto-purine.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Treat-to-target
Treat-to-flare
All participants will have the GoutSMART application installed on their phones, and be offered a management plan including the use of flare prophylaxis and maximum advised dose of allopurinol based on renal function. All Participants in the treat-to-target group will be provided with a BeneCheck hand-held device and taught to perform urate finger prick self-testing. Participants will be prompted to submit urate readings by the GoutSMART app and if urate levels remain above target their allopurinol will be increased incrementally up to the pre-specified maximum dose of allopurinol.
All participants will have the GoutSMART application installed on their phones, and be offered a management plan including the use of flare prophylaxis and maximum advised dose of allopurinol based on renal function. Participants in the treat-to-flare arm of the study will be reviewed every 4 months and allopurinol dose escalated incrementally if they have sustained a gout flare in the preceding 4 months, up to the maximum pre-specified allopurinol dose.